Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Ronald B. Moss"'
Autor:
Ronald B. Moss, Dennis J. Carlo
Publikováno v:
Substance Abuse Treatment, Prevention, and Policy, Vol 14, Iss 1, Pp 1-6 (2019)
Abstract There has been a dramatic increase of deaths due to illicit fentanyl. We examined the pharmacology of fentanyl and reviewed data on the number of repeat doses of naloxone used to treat fentanyl overdoses. Multiple sequential doses of naloxon
Externí odkaz:
https://doaj.org/article/195862f25cc24aa6b5542b0e47fe2765
Autor:
Peter J. H. Scott, Robert A. Koeppe, Xia Shao, Melissa E. Rodnick, Alexandra R. Sowa, Bradford D. Henderson, Jenelle Stauff, Phillip S. Sherman, Janna Arteaga, Dennis J. Carlo, Ronald B. Moss
Publikováno v:
Molecules, Vol 25, Iss 6, p 1360 (2020)
Naloxone (NLX) is a mu receptor antagonist used to treat acute opioid overdoses. Currently approved doses of naloxone to treat opioid overdoses are 4 mg intranasal (IN) and 2 mg intramuscular (IM). However, higher mu receptor occupancy (RO) may be re
Externí odkaz:
https://doaj.org/article/b3a836162887410ab4c332680f99c287
Publikováno v:
Advances in Virology, Vol 2011 (2011)
Influenza, respiratory synctial virus, and parainfluenza are common respiratory infections in immunocompromised transplant recipients, causing significant morbidity and mortality in this patient population. This paper focuses on influenza and parainf
Externí odkaz:
https://doaj.org/article/4dabf782f34943fdb3b7dd70c521a161
Autor:
Ronald B. Moss, Meghan McCabe Pryor, Rebecca Baillie, Katherine Kudrycki, Christina Friedrich, Mike Reed, Dennis J Carlo
Publikováno v:
Addiction Research and Adolescent Behaviour. 5:01-05
Background: Previously, we reported on an opioid receptor quantitative systems pharmacology (QSP) model to evaluate naloxone dosing. Methods: In this study we extended our model to include higher systemic levels of fentanyl (up to 100 ng/ml) and the
Publikováno v:
Addiction Research and Adolescent Behaviour. 2:01-04
Recent increases in mortality from overdoses in the US have been primarily driven by deaths due to the more potent synthetic opioids. Naloxone is an effective countermeasure to treat opioid overdose. We compared the pharmacokinetics of the three avai
Publikováno v:
Clinical Immunology (Orlando, Fla.)
COVID-19 is characterized by a dysregulation of inflammatory cytokines ultimately resulting a cytokine storm that can result in significant morbidity and mortality. We developed an in-vitro assay using activated peripheral blood mononuclear cells (PB
Autor:
Michael J. Reed, Rebecca Baillie, Meghan McCabe Pryor, Ronald B. Moss, Dennis J. Carlo, Katherine Kudrycki, Christina M. Friedrich
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234683 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234683 (2020)
Rapid resuscitation of an opioid overdose with naloxone, an opioid antagonist, is critical. We developed an opioid receptor quantitative systems pharmacology (QSP) model for evaluation of naloxone dosing. In this model we examined three opioid exposu
Publikováno v:
Journal of opioid management. 16(3)
Naloxone is an opioid antagonist used for the acute treatment of opioid overdoses. There has been a dramatic increase of deaths due to synthetic opioids such as fentanyl, some requiring multiple doses of naloxone for reversal of opioid toxicity. Fent
Autor:
Bradford D. Henderson, Phillip S. Sherman, Robert A. Koeppe, Janna Arteaga, Xia Shao, Jenelle Stauff, Peter J. H. Scott, Melissa E. Rodnick, Alexandra R. Sowa, Ronald B. Moss, Dennis J. Carlo
Publikováno v:
Molecules
Molecules, Vol 25, Iss 6, p 1360 (2020)
Volume 25
Issue 6
Molecules, Vol 25, Iss 6, p 1360 (2020)
Volume 25
Issue 6
Naloxone (NLX) is a mu receptor antagonist used to treat acute opioid overdoses. Currently approved doses of naloxone to treat opioid overdoses are 4 mg intranasal (IN) and 2 mg intramuscular (IM). However, higher mu receptor occupancy (RO) may be re
Autor:
Tatiana Bogdanovich, Rima Abdel-Massih, Diana L. Pakstis, Rebecca Routh, Fernanda P. Silveira, Ronald B Moss
Publikováno v:
Antiviral Therapy. 21:71-74
We report a cystic fibrosis patient infected with influenza 2009H1N1 who had persistent viral shedding and clinical deterioration despite prolonged treatment with oseltamivir and zanamivir. The patient was diagnosed with H275Y neuraminidase inhibitor